Medicaid Monitor
Policy Intelligence
Medicaid Monitor
Policy Intelligence
Updated Fri 12:06 PM MT
© 2026 Lanphier Ventures, LLC
Informational use only. Not legal or compliance advice.
Source
← All Sources

The Hill Healthcare

69 stories

Federal Policy·4d ago

Senate Democrats Question HHS Over Delayed Pediatric COVID Vaccine Access

Senate Minority Leader Chuck Schumer and other top Senate Democrats sent a letter to CDC Director Erica Schwartz and HHS Secretary Robert F. Kennedy Jr. questioning an apparent delay in making COVID-19 vaccines available to low-income children through a federal program. The lawmakers are seeking answers about why access through this program has stalled and what HHS plans to do to restore timely vaccine availability. The letter does not specify a response deadline in available reporting. Low-income children who rely on federally funded vaccine access programs, often coordinated with state Medicaid and CHIP populations, are the primary group affected by any delay.

Federal Policy·4d ago

Trump Administration Withholds Health Funds Before Fiscal Year Deadline

The Trump administration has declined to spend billions of dollars in congressionally appropriated health program funding, risking its expiration at the fiscal year-end on Wednesday. Democratic lawmakers and some Republicans argue the withholding violates federal law governing appropriated funds. The impasse tests whether Congress will act to compel spending of the funds before they lapse. The story does not specify which health programs or dollar amounts are affected.

Industry·4d ago

RFK Jr., Vance Headline MAHA Summit on Health Policy Agenda

HHS Secretary Robert F. Kennedy Jr. and Vice President JD Vance are leading a daylong "Make America Healthy Again" summit in Washington on Tuesday, gathering Trump administration officials, health care and tech executives, and MAHA allies. Sessions cover health care affordability, food policy, and artificial intelligence, among other topics. The event is a policy and messaging forum rather than a rulemaking action, but it signals priorities that could shape future administration health initiatives. No specific Medicaid policy announcements are described in the available details.

Industry·ME·5d ago

Democratic Super PAC Airs Ad Tying Collins to Medicaid Cuts

The Senate Majority PAC, a Democratic super PAC, launched an ad campaign attacking Sen. Susan Collins (R-Maine) over the closure of about a dozen birthing centers in Maine, linking the closures to Medicaid cuts in the One Big Beautiful Bill Act. The ad argues Collins enabled the cuts despite voting against the final legislation. The campaign is part of ongoing 2026 midterm messaging tying federal Medicaid reductions to state-level provider closures, particularly in maternal health services. No new policy or funding action is described; this is a political advertising campaign referencing prior Medicaid legislation.

Industry·5d ago

Novo Nordisk's Trial Drug Outperforms Zepbound in Weight Loss

Novo Nordisk reports that its experimental next-generation obesity drug, positioned as a successor to Wegovy, produced greater weight loss than Eli Lilly's Zepbound in a head-to-head clinical trial. The result intensifies competition in the GLP-1 weight-loss drug market between the two dominant manufacturers. No regulatory approval or launch timeline was announced, and pricing or Medicaid coverage decisions are not yet at issue. For Medicaid stakeholders, the news signals that pipeline competition in this drug class will continue to grow, with implications for future coverage and cost pressure once new products reach market.

Federal Policy·6d ago

Senate Democrats Question Kennedy Ethics Compliance on Vaccine Lawsuit Divestment

Senate Democrats are questioning whether HHS Secretary Robert F. Kennedy Jr. potentially violated his ethics agreement by allegedly concealing an arrangement to collect money from a settlement with a vaccine manufacturer. Kennedy pledged to divest from the lawsuit during his confirmation process last year. The senators' inquiry raises concerns about potential conflicts of interest at the federal agency overseeing Medicaid and other health programs. The matter is significant for Medicaid stakeholders because Kennedy's leadership of HHS includes oversight of CMS, which administers the Medicaid program and sets immunization policy affecting coverage requirements for state programs and managed care plans.

Federal Policy·11d ago

Trump Administration Terminates ACA Coverage for 750K Enrollees Citing Fraud

The Trump administration announced Tuesday it will terminate Affordable Care Act marketplace coverage for approximately 750,000 enrollees identified as fraudulent, according to Vice President Vance. The administration estimates the cancellations will save $2.2 billion in federal subsidies. CMS Administrator Dr. Mehmet Oz stated the terminated enrollments represent non-existent individuals. The announcement did not specify an effective date for the terminations or detail the criteria used to identify fraudulent enrollment.

Federal Policy·13d ago

All States Apply for CMS Medicaid Drug Pricing Program

All 50 states, Washington, D.C., and Puerto Rico have applied to participate in a CMS arrangement designed to reduce Medicaid drug costs, with 40 states and Puerto Rico already signing agreements. President Trump announced the milestone Friday, characterizing the program as delivering significant savings to state Medicaid programs. The timing and specific mechanics of the drug pricing arrangement were not detailed in the announcement. The development signals broad state interest in federal cost-containment tools for Medicaid pharmacy spending.

Federal Policy·15d ago

White House Announces 50-State Medicaid Drug Pricing Initiative

President Trump will announce that all 50 states will implement "most favored nation" pricing for certain Medicaid-covered drugs, according to an administration official. The announcement, scheduled for Friday with several governors present, would tie Medicaid drug prices to lower international reference prices. Implementation details including which drugs are covered, effective dates, and how this aligns with existing Medicaid best price and rebate requirements remain unclear. The initiative reflects ongoing White House focus on drug affordability as a voter priority.

Federal Policy·16d ago

HHS Secretary Kennedy Tells Anti-Vaccine Group Administration Supports Its Cause

HHS Secretary Robert F. Kennedy Jr. told Children's Health Defense, an anti-vaccine organization he previously led, that the Trump administration is a "strong and steadfast friend" to the group's cause. The remarks were delivered Thursday at a one-day conference. The statement signals potential alignment between federal health policy leadership and vaccine skepticism advocacy. This raises questions about future federal vaccine policy direction, including recommendations affecting Medicaid pediatric EPSDT requirements and childhood immunization standards.

Legal·TX·17d ago

Texas Family Sues Attorney General Paxton Over Denied Abortion Leading to Maternal Death

The family of Tierra Walker, a 37-year-old Texas woman who died from preeclampsia in 2024, filed a lawsuit Wednesday against Texas Attorney General Ken Paxton and doctors who denied her an abortion. Walker experienced seizures, blood clots, and hypertensive crisis at four months pregnant and requested abortion care multiple times before her death. The lawsuit challenges enforcement of Texas abortion restrictions that allegedly prevented medically necessary care. This case follows several wrongful death and civil rights lawsuits filed nationwide challenging state abortion laws and their impact on maternal health outcomes.

Federal Policy·19d ago

HHS Secretary Kennedy to Keynote Anti-Vaccine Group Conference

HHS Secretary Robert F. Kennedy Jr. is scheduled to deliver a keynote address at a Children's Health Defense conference this week. CHD is an anti-vaccine advocacy organization Kennedy co-founded and led before his appointment as HHS Secretary. Kennedy has attempted to distance himself from the organization over the past year. The appearance raises questions about potential conflicts between his official role overseeing federal health policy, including Medicaid, and his ongoing relationship with an organization that opposes vaccine mandates and promotes vaccine skepticism.

Federal Policy·19d ago

22 States Sue DHS Over Public Charge Rule Affecting Immigrant Access to Benefits

A coalition of 22 Democratic-led states and Washington, D.C., filed suit against the Department of Homeland Security to block implementation of the public charge rule. The rule restricts green card eligibility for immigrants who use or are likely to use public benefits. The litigation challenges whether DHS exceeded its authority and whether the rule violates statutory requirements. For state Medicaid agencies, the rule affects enrollment and coverage decisions for lawfully present immigrants, particularly in states that extend Medicaid eligibility beyond the federally required minimum.

Industry·23d ago

Half of Hospitals Comply with Federal Price Transparency Rules, Report Finds

Patient Rights Advocate reported that 49.4% of U.S. hospitals are in full compliance with federal price transparency requirements as of September 2026, representing the highest compliance rate since the rule took effect. The report marks the eighth assessment by the nonprofit monitoring hospital adherence to CMS price disclosure requirements. While compliance has improved incrementally, over half of hospitals remain noncompliant with federal mandates to publish machine-readable files of negotiated rates with commercial payers and cash prices.

Managed Care·26d ago

GLP-1 Prescriptions for Children Rose 30,000 Percent Since 2019

Prescriptions of GLP-1 medications for children increased more than 30,000 percent between 2019 and present, according to new data. Children with obesity-related conditions such as high cholesterol or sleep apnea were substantially more likely to receive GLP-1 prescriptions than those without these comorbidities. The dramatic rise in pediatric GLP-1 use reflects growing clinical acceptance of these medications for weight management in children with obesity-related health complications. This trend has significant implications for Medicaid managed care pharmacy budgets and prior authorization protocols, as GLP-1s are high-cost specialty medications and children represent a growing share of Medicaid enrollment.

Legal·27d ago

Fifth Circuit to Hear Mifepristone Access Case Amid Medicaid Coverage Implications

A three-judge panel on the Fifth Circuit Court of Appeals will hear oral arguments in a case challenging nationwide distribution of mifepristone, the medication abortion drug. The case could result in restrictions on mifepristone access that would affect Medicaid beneficiaries and state Medicaid pharmacy programs. Oral arguments are scheduled for next week, with a decision timeline uncertain. The outcome could require state Medicaid agencies and managed care plans to adjust pharmacy benefits, provider networks, and utilization management protocols for medication abortion services covered under Medicaid.

Industry·30d ago

Bipartisan House Bill Proposes $35 Monthly Insulin Cap for Private Insurance

House lawmakers introduced bipartisan legislation Thursday to cap monthly insulin costs at $35 for people with private health insurance. The bill includes support from two battleground Republicans, marking a shift from previous GOP resistance to government price-setting. If enacted, the cap would affect privately insured patients; Medicaid beneficiaries already benefit from rebate protections and state-specific cost-sharing limits that often result in lower out-of-pocket costs. The legislation has been discussed for years but has not previously advanced due to concerns about government price controls.

Federal Policy·30d ago

Democrats Debate Healthcare Reform Priorities Ahead of 2026 Midterms

Democratic lawmakers and policy groups are proposing various healthcare reform options as the party campaigns to retake Congress in the 2026 midterm elections. The debate follows the 2025 expiration of enhanced ACA premium tax credits, with no current legislative momentum to extend them. Proposals under discussion range from incremental ACA fixes to more expansive reforms. The outcome will depend on election results and intraparty consensus on how aggressively to pursue healthcare changes, which could affect Medicaid expansion efforts, marketplace subsidies that interact with Medicaid eligibility, and broader coverage policy.

Federal Policy·32d ago

Acting Attorney General Signals Federal Action to Restrict Abortion Access in All States

Acting Attorney General Todd Blanche told faith leaders on a private call hosted by the White House Faith Office that he plans to roll back abortion access nationwide, including in states with protective abortion laws. Blanche indicated the administration intends to reverse Biden-era protections for abortion access. The timeline and specific legal mechanisms for federal intervention were not detailed in available reporting. The development is significant for state Medicaid agencies and managed care organizations that cover abortion services under state law, potentially creating conflicts between federal directives and state coverage obligations.

Federal Policy·32d ago

Trump Executive Order Reduces Recommended Childhood Vaccine Schedule to 11 Core Immunizations

President Trump signed an executive order Monday advancing 'Make America Healthy Again' priorities by recommending 11 core childhood vaccinations instead of the current CDC schedule and directing agencies to split combined vaccines. The order takes effect immediately but applies only to federal recommendations, not state Medicaid EPSDT requirements, which mandate coverage of ACIP-recommended immunizations under federal law. The directive creates potential conflict between federal guidance and mandatory Medicaid Early and Periodic Screening, Diagnostic and Treatment benefits. State Medicaid agencies and managed care plans must continue covering all ACIP-recommended vaccines to maintain federal compliance and avoid audit findings.

Federal Policy·33d ago

Trump Administration Announces Medicaid Drug Pricing Agreements with Nine Companies

The Trump administration announced new Medicaid drug pricing agreements with nine midsize biotechnology and pharmaceutical companies. Under the agreements, companies will charge state Medicaid programs prices equal to the lowest available globally. President Trump stated the deals will apply to every drug from participating firms. The announcement was made Monday in the Oval Office with company executives present.

Legal·37d ago

23 States Sue Trump Administration Over Family Planning Grant Requirements

A coalition of 23 states filed suit in Maryland federal court Thursday challenging new conditions on family planning grants that would allegedly require states and providers to align with administration political priorities or lose federal funding. The lawsuit contests restrictions that could affect Title X family planning program funding, which supports reproductive health services including contraception and preventive care for Medicaid beneficiaries. The litigation seeks to block implementation of the new grant requirements. The outcome will determine whether states retain existing federal family planning funding or must choose between compliance with new federal conditions and maintaining current service delivery models.

Federal Policy·39d ago

Senate Democrats Question HHS Secretary Kennedy on HPV Vaccine Lawsuit Divestment

Senate Democrats are scrutinizing whether HHS Secretary Robert F. Kennedy Jr. fully divested his financial interests in ongoing litigation against Merck's HPV vaccine Gardasil before his confirmation. Kennedy was involved in a lawsuit led by Wisner Baum challenging the vaccine prior to his appointment. The inquiry raises questions about potential conflicts of interest at the top of the agency that oversees Medicaid coverage policy, vaccine programs, and federal health initiatives. The matter could affect federal vaccine policy direction and Medicaid immunization coverage decisions.

Industry·40d ago

GLP-1 Medications Show Potential to Treat Addiction, Emerging Research Suggests

Emerging research indicates that GLP-1 medications, widely used for obesity and diabetes treatment, may help treat addiction disorders. The studies add to a growing list of unanticipated effects associated with this drug class. The findings are preliminary and do not yet reflect approved indications or clinical practice guidelines. If further research confirms these effects and leads to FDA approval for addiction treatment, Medicaid programs could face coverage decisions for a new high-cost indication with significant budget implications.

Federal Policy·41d ago

HHS Secretary Kennedy Implements Executive Order Reducing Childhood Vaccines

President Trump signed an executive order to reduce childhood vaccines, with HHS Secretary Robert F. Kennedy Jr. present and implying a link between vaccines and autism. The order affects federally-funded vaccine programs, including those administered through Medicaid and CHIP. Implementation details and timing are not yet specified. The change carries implications for state Medicaid agencies and managed care plans responsible for EPSDT requirements and vaccine coverage mandates.

Federal Policy·41d ago

CMS Administrator Oz States MMR Vaccine Not Lethal, Contradicts Trump

Dr. Mehmet Oz, CMS Administrator, stated publicly that the MMR vaccine is not lethal, contradicting President Trump's characterization. The statement was made during a CBS News interview on August 23, 2026. This matters for Medicaid because CMS oversees Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefits, which require comprehensive immunizations for eligible children, including MMR. Any policy shift on vaccine guidance from CMS leadership could affect state Medicaid agency compliance with federal EPSDT requirements and managed care organization vaccine administration protocols.

Federal Policy·44d ago

Estrogen Patch Shortage Continues as Manufacturers Cite Federal Policy-Driven Demand Spike

Pharmaceutical manufacturers report ongoing supply shortages of estrogen patches in the U.S., attributing the shortage to increased demand following federal policy changes implemented earlier in 2026. The manufacturers flagged supply issues earlier this year but federal regulators have not yet officially recognized a shortage. The continued supply constraints affect Medicaid beneficiaries' access to hormone replacement therapy, potentially forcing plans and providers to manage formulary alternatives and prior authorization processes for affected members seeking this form of estrogen therapy.

Legal·45d ago

Federal Court Blocks Trump Administration Changes to Teen Pregnancy Prevention Grants

A federal district court in Washington, D.C., issued a temporary injunction halting the Trump administration's changes to the Teen Pregnancy Prevention (TPP) program that cut tens of millions in federal grants. The order pauses the administration's changes pending further litigation. The ruling affects organizations that lost federal funding abruptly under the policy shift. The injunction takes effect immediately.

Industry·45d ago

Trump Nominates White House Health Adviser Heidi Overton as FDA Commissioner

President Trump announced Wednesday he will nominate Dr. Heidi Overton, currently a White House domestic policy adviser on health issues, to serve as FDA Commissioner. The nomination comes amid significant staff turnover at the agency. If confirmed by the Senate, Overton would lead the FDA's oversight of prescription drugs, including Medicaid drug coverage policy and pharmaceutical manufacturer rebates. The nomination's impact on Medicaid will depend on Senate confirmation timing and Overton's policy priorities once in office.

Legal·46d ago

Democratic Senators Accuse HHS of Violating Court Order on Medicaid Data Sharing with ICE

Four Democratic senators accused the Trump administration of violating a court order by continuing to share Medicaid enrollment data with DHS and ICE for deportation proceedings. Sens. Wyden, Booker, Merkley, and Van Hollen demanded HHS immediately halt the data sharing practice. The complaint alleges ongoing transfers of beneficiary information despite judicial restrictions. The disclosure raises compliance and enrollment concerns for state Medicaid agencies managing beneficiary data and MCOs responsible for protecting member information under privacy regulations.

Federal Policy·53d ago

March of Dimes: 5.8 Million Women Live in Maternity Care Deserts

A March of Dimes report finds that 5.8 million women live in counties without full access to maternity care, with one-third of U.S. counties classified as maternity care deserts — areas lacking hospitals or birth centers offering obstetric services. The report highlights geographic disparities in prenatal and delivery care access nationwide. These gaps affect Medicaid-covered pregnancies, as Medicaid finances approximately 42% of births nationally and faces network adequacy and provider participation challenges in underserved areas.

Industry·53d ago

Research Suggests GLP-1 Drugs May Reduce Birth Control Effectiveness and Boost Fertility

Emerging research indicates that GLP-1 receptor agonist medications may interfere with oral contraceptive effectiveness and potentially increase fertility in users. The mechanism appears related to GLP-1s' effects on gastric emptying and hormone metabolism, which could reduce contraceptive absorption and alter reproductive hormone levels. The timing and clinical significance remain under investigation, but the findings have immediate implications for prescribing guidance and patient counseling. For Medicaid programs covering GLP-1s for diabetes and obesity, this raises questions about contraceptive coverage coordination, prior authorization criteria, and member education protocols.

Federal Policy·60d ago

HHS Secretary Kennedy Endorses Measles Vaccine Amid Outbreak Discussions

Health and Human Services Secretary Robert F. Kennedy Jr. endorsed the measles vaccine during a CNN interview on August 3, 2026, while making additional claims about other vaccines and RSV during ongoing measles outbreaks. The statement represents the Secretary's public position on measles immunization policy as the nation's top health official. The endorsement comes as federal and state health agencies manage measles outbreak response and vaccination campaigns. HHS guidance on childhood vaccinations influences state Medicaid EPSDT requirements, managed care quality metrics, and VFC program administration.

Legal·61d ago

HRC Sues Trump Administration Over Gender-Affirming Care Coverage Ban in Federal Employee Health Plans

The Human Rights Campaign filed a class-action lawsuit Monday challenging the Trump administration's ban on gender transition treatment coverage in federal employee health plans. The suit alleges the coverage ban violates federal sex discrimination protections in employment. The lawsuit does not directly target Medicaid or CHIP programs, though similar coverage restrictions could inform future Medicaid policy debates. The case centers on Federal Employees Health Benefits Program coverage, not state Medicaid programs.

Federal Policy·62d ago

HHS Secretary Kennedy Says Trump Directed Investigation of Autism-Vaccine Link

HHS Secretary Robert F. Kennedy Jr. stated in a CNN interview that President Trump has directed him to investigate perceived links between autism and vaccines. Kennedy confirmed the Wall Street Journal's reporting on the matter. The statement signals potential federal review of vaccine policy and safety monitoring under the current administration. No timeline or specific investigative framework has been announced.

Federal Policy·66d ago

Bipartisan Bill Directs CMS to Add Stuttering Screening to EPSDT

Sens. Jim Banks (R-Ind.) and Andy Kim (D-N.J.) introduced the Kidd's Stuttering Act on Wednesday, directing CMS to add stuttering and fluency screening to Early and Periodic Screening, Diagnostic and Treatment (EPSDT) services. The legislation would require Medicaid to cover screening and treatment for stuttering in children enrolled in the program. If enacted, state Medicaid agencies and managed care organizations would need to ensure network adequacy for speech-language pathology services and update coverage policies to include fluency disorder screening as part of well-child visits.

Federal Policy·69d ago

FDA Raises Safety Concerns About Compounded GLP-1 Drugs as Alternative to Ozempic

The FDA and physicians are expressing concern about compounded versions of GLP-1 drugs like Ozempic, which patients are increasingly using as cheaper, more accessible alternatives. These compounded formulations, while easier to obtain, carry serious safety risks according to medical experts. The issue affects Medicaid beneficiaries who may turn to compounded versions due to cost or access barriers with brand-name GLP-1s. This raises questions for state Medicaid programs about coverage policies, prior authorization criteria, and quality oversight for diabetes and weight management drugs.

Industry·69d ago

Danish Study Finds GLP-1 Drugs Reduce Long-Term Sick Leave by 17%

A study based on Danish data found that patients taking GLP-1 drugs experienced 17% fewer long-term work absences compared to those not on the medications. The research examined workplace absenteeism patterns among GLP-1 users. The findings suggest potential broader economic benefits beyond direct health outcomes. For Medicaid programs covering GLP-1s for weight management or diabetes, this data may inform cost-benefit analyses around coverage decisions, though workforce participation effects in Medicaid populations may differ from the Danish workforce studied.

Industry·71d ago

Study Finds GLP-1 Drugs Reduce Long-Term Sick Leave by 17 Percent

A study using Danish data found that patients taking GLP-1 medications had 17 percent fewer long-term sick leave absences compared to those not on the drugs. The research suggests potential workforce participation and productivity benefits beyond clinical outcomes for obesity and diabetes treatment. The findings may inform Medicaid coverage decisions and utilization management policies for GLP-1s, which have been subject to state budget scrutiny due to high costs. The study did not specify implementation timelines but reflects ongoing evaluation of these drugs' broader economic impacts.

Federal Policy·73d ago

Trump Announces 100% Tariff on Imported Generics Effective August 2028

President Trump announced Tuesday via social media that imported generic drugs will face a 100 percent tariff beginning in August 2028 unless manufacturers relocate production to the United States. The tariff is described as a penalty designed to reshore generic pharmaceutical manufacturing. Generic drugs constitute the majority of Medicaid pharmacy spending, and most generics dispensed in the U.S. are manufactured overseas or contain active pharmaceutical ingredients from foreign suppliers. The two-year implementation timeline provides MCOs and state programs time to assess potential pharmacy cost impacts and supply chain disruptions.

Federal Policy·74d ago

Senate Democrat Proposes Medicare Enrollment for All Children Under Age 26

Sen. Andy Kim (D-N.J.) introduced legislation to automatically enroll all American children in Medicare from birth through age 25, calling the proposal MediKids. The bill would create universal federal coverage for children regardless of family income. No timeline for committee consideration or floor action has been announced. The proposal would fundamentally restructure pediatric coverage currently delivered through Medicaid, CHIP, and commercial insurance, though passage prospects remain uncertain given divided government.

Federal Policy·76d ago

Medicare Part D Now Covers GLP-1s for Weight Loss Under New CMS Policy

Insurance coverage for GLP-1 medications used for weight loss has changed for approximately 56 million Americans. The policy shift affects Medicare Part D beneficiaries and potentially other federal health programs. The coverage expansion comes as GLP-1 drugs like Ozempic and Wegovy gain widespread use for obesity treatment. Medicare previously covered these medications only for diabetes, not weight management alone, making this a significant benefit expansion with major cost implications for plans and enrollees.

Federal Policy·76d ago

Planned Parenthood Medicaid Funding Prohibition Excluded from GOP Reconciliation Framework

Republicans' reconciliation 3.0 framework omits language that would prohibit Medicaid funding from flowing to abortion providers like Planned Parenthood, prompting intensified activism from anti-abortion groups. The exclusion marks a potential shift in Republican legislative strategy on reproductive health provider funding within Medicaid. No timeline for final reconciliation language has been announced. The omission affects managed care organizations that currently contract with or reimburse Planned Parenthood affiliates for covered Medicaid services in states that have not already enacted provider exclusions.

Federal Policy·79d ago

Senate Questions CDC and HHS Nominees on Vaccine Policy Alignment

Two Trump administration health nominees—Erica Schwartz for CDC Director and Sean Kaufman for an HHS position—faced Senate scrutiny on July 15, 2026, over their willingness to challenge administration positions on vaccines. Both Democrats and some Republicans expressed concern about the nominees' reluctance to break with administration policy. The hearing centered on whether the nominees would maintain agency independence on vaccine policy and public health guidance. Confirmation votes have not been scheduled.

Federal Policy·80d ago

Acting AG Pledges Federal Action to Restrict Mail Order Mifepristone

Acting Attorney General Todd Blanche told Republican senators he will prioritize stopping abortion medication from being mailed to patients if confirmed. Blanche specifically opposes the Biden-era policy that permitted mail distribution of mifepristone but did not detail enforcement mechanisms or timeline. The commitment signals potential federal action against telehealth abortion services and mail-order pharmacy dispensing of medication abortion. Any DOJ enforcement action could affect Medicaid managed care plans that cover telehealth reproductive services and pharmacy benefits including mifepristone.

Federal Policy·83d ago

HHS Secretary Kennedy Blocks Preventive Services Task Force Meetings, Fires Leadership

HHS Secretary Robert F. Kennedy Jr. has prevented the U.S. Preventive Services Task Force from meeting, declined to replace members whose terms have expired, and fired the panel's leaders in May 2026. The task force determines which preventive medical services insurers must cover without cost-sharing under the Affordable Care Act. The disruption affects coverage recommendations for screenings, counseling, and preventive medications that Medicaid managed care plans must cover as essential health benefits. The timeline for new coverage recommendations and the panel's future composition remain uncertain.

Federal Policy·87d ago

FDA Approves Gene Therapy for Children with Sickle Cell Disease

The FDA has approved a new gene therapy treatment for children aged 2 and older with sickle cell disease. The approval expands treatment options for pediatric patients with this serious inherited blood disorder, which disproportionately affects Medicaid beneficiaries. Sickle cell disease affects approximately 100,000 Americans, with the majority covered by Medicaid. Managed care organizations will need to evaluate coverage policies, establish prior authorization criteria, and assess the financial impact of this high-cost specialty therapy on capitation rates and medical loss ratios.

Managed Care·88d ago

GLP-1 Weight Loss Use Jumps to 11% of Americans in Two Years

A Gallup survey released Tuesday shows 11 percent of Americans now take GLP-1 medications for weight loss, up from 3 percent in 2024. An additional 15 percent report considering use. The sharp uptick in utilization represents significant pharmacy cost pressure for Medicaid managed care plans, which face coverage mandates in some states and growing member demand. Plans must manage prior authorization protocols, medical necessity criteria, and budget forecasts as obesity prevalence grows among Medicaid populations.

Federal Policy·93d ago

DEA Proposes Schedule I Classification for Synthetic Kratom Compound 7-OH

The Drug Enforcement Administration announced plans to temporarily classify 7-hydroxymitragynine (7-OH) and three related synthetic kratom compounds as Schedule I controlled substances, placing them in the same regulatory category as heroin and LSD. The classification applies to synthetic versions of the psychoactive compound found in kratom products. If finalized, the scheduling action would prohibit manufacture, distribution, and possession of these substances, with enforcement implications for entities handling these compounds. The timing of implementation and comment period was not specified in the available content.

Industry·96d ago

PBM Trade Group Escalates Advocacy Against Drugmakers Following Congressional Overhaul

The leading pharmacy benefit manager lobbying organization is intensifying its advocacy campaign against pharmaceutical manufacturers after Congress enacted comprehensive PBM reform legislation earlier this year. The pharmaceutical industry has long blamed PBMs for high drug costs, culminating in legislative action this past winter. The lobbying escalation suggests ongoing tension between PBMs and drugmakers over responsibility for drug pricing and the implementation of new federal oversight provisions that affect both sectors.

Federal Policy·97d ago

Sanders Releases HHS Emails Showing Kennedy Pressured CDC on Vaccine Messaging

Senator Bernie Sanders released internal HHS emails indicating that HHS Secretary Robert F. Kennedy Jr. pressured the CDC to alter vaccine messaging and directed the CDC's vaccine advisory panel to restrict vaccine access. The emails document direct intervention in CDC communications and advisory processes. The release comes amid ongoing scrutiny of the administration's vaccine policy direction and its potential impact on public health programs.

Legal·NY·101d ago

Federal Judge Blocks DOJ Subpoenas for Transgender Patient Records at NYC Hospitals

A federal district court issued a temporary restraining order blocking the Justice Department from obtaining medical records of transgender patients treated at New York City hospitals. The ruling halts an ongoing DOJ investigation into gender-affirming care provided at these facilities. The order provides immediate protection for patient records while the case proceeds. The decision affects hospitals treating Medicaid beneficiaries receiving gender-affirming services and raises questions about federal enforcement priorities and patient privacy protections.

Federal Policy·101d ago

Senate Democrats Challenge Trump Administration's Moms.gov Site Over Crisis Pregnancy Center Listings

Eleven Democratic senators raised concerns about the Trump administration's Moms.gov website, launched on Mother's Day, which features resources from 2,750 pregnancy centers. The lawmakers argue the site directs families to crisis pregnancy centers rather than licensed medical providers. The site provides information for new and expecting mothers, but critics including Planned Parenthood contend these centers do not provide comprehensive medical care. The senators' letter signals potential congressional oversight of federal maternal health resource guidance.

Industry·104d ago

Meta-Analysis Compares Weight Loss Efficacy Across Tirzepatide, Semaglutide, and Liraglutide

A new meta-analysis compared weight loss outcomes for three GLP-1 receptor agonists: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza). The study evaluated clinical efficacy data across the three drug classes to determine comparative effectiveness for weight management. The findings provide evidence that could inform prior authorization criteria, formulary placement, and medical policy for obesity treatment in Medicaid managed care plans. Many state Medicaid programs have restricted or excluded coverage of anti-obesity medications due to cost, making comparative effectiveness data particularly relevant for coverage and utilization management decisions.

Federal Policy·107d ago

Senate Democrats Investigate HHS Changes to Federal Vaccine Advisory Panel

Senate Democrats Ron Wyden and Maggie Hassan have launched an investigation into Health Secretary Robert F. Kennedy Jr.'s restructuring of the Advisory Committee on Immunization Practices (ACIP), the federal panel that issues vaccine recommendations. The senators are demanding communications and records showing who determined the legal and public health consequences of remaking the advisory committee. ACIP recommendations typically inform Medicaid and CHIP coverage decisions for vaccines under the Vaccines for Children program and mandatory coverage requirements for pediatric vaccines. The investigation seeks transparency around the decision-making process that led to changes in the federal vaccine policy infrastructure.

Federal Policy·109d ago

FDA Approves Third Over-the-Counter Naloxone Nasal Spray

The FDA approved Rextovy, a 4mg naloxone nasal spray, for over-the-counter sale in pharmacies, convenience stores, and online for emergency treatment of opioid overdose. This is the third OTC naloxone product approved by FDA. The approval expands consumer access to overdose reversal medication without a prescription. For Medicaid managed care organizations, this may affect pharmacy benefit management, member education strategies, and harm reduction program design, particularly for plans serving populations with substance use disorders.

Federal Policy·109d ago

Senate Democrats Release Prescription Drug Pricing Policy Blueprint

Senate Democrats released a policy blueprint proposing measures to lower prescription drug costs ahead of the midterm elections. The proposals aim to address voter concerns about drug affordability and provide a counter-message to White House voluntary pricing initiatives. The blueprint reflects ongoing bipartisan interest in drug pricing reform but does not specify legislative text, implementation timelines, or comment periods. For Medicaid managed care organizations, potential reforms could affect pharmacy benefit management, capitation rate calculations, and prescription drug rebate programs.

Federal Policy·110d ago

HHS Secretary Kennedy Demands Explanation for Retracted Vaccine-SIDS Study

HHS Secretary Robert F. Kennedy Jr. sent a June 11 letter to the editor-in-chief of Toxicology Reports demanding justification for the removal of a 2021 study linking vaccines to sudden infant death syndrome. Kennedy has cited this research in support of proposed changes to childhood immunization schedules. The retraction raises questions about the scientific basis for potential federal policy shifts affecting Medicaid-covered pediatric vaccine programs. No timeline has been announced for HHS policy changes to childhood vaccination requirements.

Legal·AK·114d ago

Planned Parenthood Sues Alaska Over Medication Abortion Telehealth Ban

Planned Parenthood Great Northwest filed a lawsuit Thursday in Alaska state court challenging the state's requirement that medication abortion be provided only in person, arguing it violates Alaska's constitutional right to abortion. The lawsuit seeks a preliminary injunction against the telehealth ban. Alaska is among states restricting medication abortion access through telehealth despite broader telemedicine expansion. The case affects how Medicaid managed care plans handle abortion coverage and telehealth protocols in Alaska, particularly for reproductive health services where telehealth has become standard in other states.

Federal Policy·115d ago

Six States Report Higher-Than-Expected ACA Marketplace Attrition After Enhanced Subsidies Expired

State-level enrollment data through April 2026 from Arkansas, Colorado, Maryland, Massachusetts, New Mexico, and New York show significant coverage losses as enrollees canceled plans or stopped paying premiums following the expiration of enhanced ACA subsidies. Georgetown University analysis indicates attrition rates exceed initial federal projections. Congress did not renew the enhanced subsidies that had been in place, resulting in higher premium costs for marketplace enrollees. The coverage losses could affect Medicaid managed care organizations in states with integrated or coordinated care models between marketplace and Medicaid coverage.

Federal Policy·115d ago

ACOG Issues Maternal Vaccine Schedule Diverging from CDC Guidance

The American College of Obstetricians & Gynecologists released a recommended maternal vaccine schedule that differs from CDC guidance for the first time. ACOG recommends four vaccines during pregnancy: influenza, COVID-19, Tdap, and RSV. The new schedule affects prenatal care protocols and provider counseling for pregnant Medicaid beneficiaries. This divergence creates potential confusion for managed care organizations that must decide whether to align coverage policies and quality metrics with CDC or ACOG recommendations for their maternal health programs.

Industry·118d ago

Trump Administration Adds 160 Drugs to TrumpRx Direct-to-Consumer Platform

President Trump announced Friday that TrumpRx.gov will add 160 prescription medications to its direct-to-consumer platform, bringing the total to over 800 drugs available at discounted prices. This marks the second expansion of the initiative in two months. The platform sells drugs directly to consumers, bypassing traditional pharmacy channels. The announcement did not specify which drugs were added or provide details about pricing structures or manufacturer participation.

Federal Policy·120d ago

CDC Reports Over 2,000 Measles Cases in 2026, 93% Outbreak-Related

The CDC confirmed 2,030 measles cases in the U.S. as of June 4, 2026, with 1,890 cases (93%) linked to outbreaks. This total is rapidly approaching the full-year 2025 count. Measles is a highly contagious vaccine-preventable disease that poses particular risks to immunocompromised populations and young children. For Medicaid managed care plans, rising case counts may trigger increased EPSDT screening requirements, higher utilization of pediatric acute care and emergency services, and potential quality measure impacts related to childhood immunization rates.

Federal Policy·120d ago

FDA Launches Safety Review of Abortion Drug Mifepristone

The Food and Drug Administration has initiated a safety review of mifepristone, the abortion medication, according to an administration official. The retrospective analysis could lead to restrictions on the drug's use and distribution channels. Anti-abortion groups view this as a significant development that may result in tighter federal controls over medication abortion access. The timing and scope of the review have not been disclosed.

Federal Policy·121d ago

Senator Cassidy Blames HHS Secretary Kennedy for Rise in Vaccine-Preventable Diseases

Sen. Bill Cassidy (R-La.) publicly blamed HHS Secretary Robert F. Kennedy Jr. for a resurgence in vaccine-preventable diseases, citing a New York Times report that hospitals are seeing illnesses previously controlled by childhood immunizations. The statement comes as doctors report increased cases of diseases they rarely encountered in recent years. The criticism targets Kennedy's well-documented skepticism of vaccines and his influence over federal health policy. No immediate policy change or enforcement action has been announced.

Legal·HI·121d ago

HHS OIG Defunds Hawaii Medicaid Fraud Control Unit After Four Years Without Indictments

The HHS Office of Inspector General will not recertify Hawaii's Medicaid Fraud Control Unit, cutting off $3 million in federal funding after the unit failed to produce any indictments or convictions over four years. Inspector General March Bell notified Hawaii Attorney General Anne Lopez of the decision in a letter. The decertification means Hawaii loses federal matching funds for its MFCU operations. This is the first known instance of OIG defunding a state MFCU for performance failure.

Federal Policy·123d ago

CMS Administrator Oz to Lead White House Press Briefing

Dr. Mehmet Oz, Administrator of the Centers for Medicare and Medicaid Services, will conduct the White House press briefing on Tuesday. He is filling in for press secretary Karoline Leavitt during her maternity leave, joining other Cabinet officials who have taken on briefing duties. The briefing may provide insight into CMS priorities and policy direction under the current administration. Managed care organizations should monitor for any announcements regarding Medicaid policy, regulatory changes, or administrative guidance that could affect program operations.

Federal Policy·126d ago

Trump Executive Order Endorses HHS Reduction in Required Childhood Vaccinations

President Trump signed an executive order Friday endorsing HHS's decision to reduce required childhood vaccinations. The order cites religious liberty and parental rights as justification for adjusted immunization requirements. The policy change affects federally recommended vaccine schedules that states and health plans use for EPSDT and well-child care compliance. Medicaid managed care organizations must monitor whether state Medicaid agencies adjust their EPSDT screening requirements in response, which could impact quality metrics, HEDIS measures, and contractual performance standards tied to childhood immunization rates.

Managed Care·127d ago

UnitedHealthcare Eliminates Two-Thirds of Pediatric Prior Authorization Requirements by Year-End

UnitedHealthcare announced it will remove prior authorization requirements for the majority of pediatric services for members under age 18 by the end of the year, eliminating two-thirds of current authorization requirements. The change affects commercial and Medicare Advantage plans with pediatric enrollment. The policy takes effect by December 31, 2024. This reflects growing pressure on health plans to reduce administrative burden and aligns with broader industry and regulatory momentum toward prior authorization reform, potentially setting a benchmark other Medicaid MCOs may need to match.

Get the daily briefing.